An Ebola outbreak in northeastern Democratic Republic of Congo that has now spread into neighboring Uganda is raising renewed global concern over the virus’ containment, as health authorities struggle with a rare strain for which no approved vaccine or antibody treatment currently exists.
The outbreak, driven by the Bundibugyo ebolavirus, has already resulted in more than 220 suspected deaths, according to the World Health Organization (WHO), which warned on May 25 that the spread of the disease is outpacing response efforts. Treatment facilities in the conflict-affected east of Congo have also reportedly come under attack, further complicating containment operations.
Ebola remains one of the most lethal infectious diseases known, with fatality rates that in some outbreaks have reached up to 90 percent. Because of its severity, governments and global health agencies treat Ebola outbreaks as national security threats requiring urgent international coordination.
The current situation highlights both the biological danger of the virus and the operational challenges of responding in regions affected by conflict, displacement and weak health infrastructure.
The current outbreak has been identified as being caused by the Bundibugyo strain of Ebola, a rare form of the virus first detected in western Uganda in 2007. Before the current crisis, only two major outbreaks involving this strain had been recorded, including one in eastern Congo in 2012.
Unlike the more widely studied Zaire ebolavirus, which has been responsible for the largest and most deadly Ebola epidemics in history, Bundibugyo remains significantly less understood. This knowledge gap has major consequences for outbreak response.
Most existing Ebola vaccines and antibody-based treatments were developed specifically to target the Zaire strain following the devastating West African epidemic between 2013 and 2016, which killed more than 11,000 people across Guinea, Liberia and Sierra Leone, and later spread to other countries including isolated cases in Europe and the United States.
As a result, there are currently no approved vaccines or licensed monoclonal antibody treatments specifically designed to protect against Bundibugyo ebolavirus infections. While some antiviral drugs such as remdesivir have been considered in certain cases, their effectiveness against this strain remains limited and not formally approved.
Ebola virus disease is caused by viruses in the orthoebolavirus family, primarily found in sub-Saharan Africa. Scientists have identified six species of Ebola virus, though only four are known to cause disease in humans.
The virus is believed to originate in wildlife and can spill over into humans through direct contact with infected animals such as bats, chimpanzees and gorillas. Once transmitted to humans, it spreads through direct contact with bodily fluids, including blood, vomit, urine, sweat and other contaminated materials.
Health workers and family caregivers are among the most vulnerable groups during outbreaks due to their close contact with infected patients.
Unlike airborne diseases such as COVID-19, Ebola does not spread easily through casual contact. Transmission typically requires close physical exposure, particularly during the later stages of illness or after death, when viral loads are highest.
Early symptoms include fever, fatigue, muscle pain, headache and sore throat. These may progress to vomiting, diarrhea, internal bleeding and in some cases external bleeding. The virus attacks multiple organs and can lead to shock, organ failure and death if untreated.
Some survivors experience long-term complications such as chronic pain, neurological disorders and vision problems. In certain cases, the virus can persist in immune-privileged parts of the body, including the eyes, central nervous system and reproductive organs, potentially allowing delayed complications or rare transmission after recovery.
As of May 25, health authorities in Congo reported 101 confirmed Ebola infections, alongside 930 suspected cases and 221 suspected deaths. Just ten days earlier, the number of deaths attributed to the outbreak stood at 65, showing a rapid escalation.
The outbreak is centered in Ituri province, a remote and conflict-affected region in eastern Congo located more than 1,700 kilometers from the capital, Kinshasa. The area has limited healthcare infrastructure, poor road networks and ongoing armed group activity, all of which hinder emergency response efforts.
Mongbwalu, a gold-mining hub in the region, has emerged as a key hotspot. The area sees frequent movement of workers between mining camps and trading centers, increasing the risk of wider transmission. Cases have also been reported in Bunia, the provincial capital, which has a population of nearly 700,000 people.
Cross-border movement between Congo, Uganda and South Sudan has raised concerns about regional spread. Uganda has already recorded infections linked to travelers arriving from Congo, underscoring the porous nature of borders in the region.
The World Health Organization declared the outbreak a Public Health Emergency of International Concern (PHEIC), its second-highest alert level, one week before its May 25 update. The designation is used for outbreaks that pose significant cross-border risks and require coordinated international response measures.
Past PHEIC declarations have included COVID-19, mpox, polio and earlier Ebola outbreaks. The classification does not necessarily indicate a global pandemic is imminent, but it is intended to mobilize funding, technical assistance and preparedness measures.
WHO has urged affected countries and neighboring states to strengthen disease surveillance, laboratory testing, contact tracing, border screening and treatment readiness to reduce the risk of further spread.
Congo is one of the most experienced countries globally in managing Ebola outbreaks, having responded to more than a dozen epidemics since the virus was first identified near the Ebola River in 1976. Over time, the country has developed systems for rapid diagnostics, contact tracing and community engagement.
Its most recent outbreak, which ended in December 2025, was contained within six weeks, demonstrating improved response capacity despite ongoing challenges.
However, the current outbreak is exposing deep vulnerabilities in eastern Congo, where armed conflict, population displacement and mistrust of authorities continue to undermine containment efforts.
Health facilities in the region have come under increasing pressure, with reports of violence disrupting treatment efforts. At least 25 patients reportedly fled Ebola treatment centers in Ituri after facilities were attacked and isolation tents were destroyed, according to local hospital sources cited in reporting.
Such incidents make it more difficult to isolate patients and trace contacts, both of which are essential to controlling Ebola transmission. Unsafe burial practices, often carried out during community unrest or mistrust of medical teams, can also significantly increase infection risks.
At the same time, reductions in international health funding and emergency assistance programs have raised concerns about weakened outbreak response capacity in fragile regions. These programs have historically supported laboratory systems, epidemiological training and vaccine deployment efforts during past outbreaks.
The United States previously played a major role in Ebola response operations through agencies such as the Centers for Disease Control and Prevention and USAID, providing technical and financial support during major epidemics.
There is no universal cure for Ebola, but early supportive treatment significantly improves survival rates. Patients typically receive intravenous fluids, electrolyte replacement, oxygen support and medications to stabilize blood pressure and manage secondary infections.
For the Zaire strain, two antibody-based therapies and the Ervebo vaccine have been approved and widely deployed in outbreak settings. These tools have proven highly effective in controlling transmission through ring vaccination strategies targeting contacts of infected individuals and frontline health workers.
However, these interventions are not approved for the Bundibugyo strain, leaving a critical gap in medical defenses against the current outbreak.
At present, no widely approved vaccines exist for Bundibugyo ebolavirus, highlighting the urgent need for expanded research and development into broader Ebola countermeasures capable of targeting multiple strains.
